N/A
Completed N=20
Oral Contraceptives and Subantimicrobial Doxycycline: Effect on Endometrial Matrix Metalloproteinases
Breakthrough Bleeding
Source: ClinicalTrials.gov NCT01469585 ↗
Enrolled (actual)
20
Serious AEs
0.0%
Results posted
Dec 2020
Primary outcomePrimary: Endometrial Matrix Metalloproteinase Expression by Gel Densitometry — 1.33; 2.49 relative expression
Summary
The purpose of this study is to compare the effects (good and bad) of subantimicrobial dose doxycycline on the irregular bleeding women experience when taking continuous oral contraceptive pills. This research is being done because currently, there is no effective treatment for this condition. Findings from this study could help to decrease the side effects of birth control pills and decrease unplanned pregnancies.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Endometrial Matrix Metalloproteinase Expression by Gel Densitometry |
1.33; 2.49 | — |
| SECONDARY Matrix Metalloproteinase Expression and Activity by Gel Densitometry |
1.52; 1.98 | — |
Eligibility Criteria
Inclusion Criteria
- Women between the ages 18 and 45 who are ovulatory as demonstrated by a pre-treatment Progesterone (P) greater than or equal to 3.0 ng/mL prior to oral contraceptive use
Exclusion Criteria
- Women with any absolute contraindications to ethinyl estradiol and levonorgestrel;
- Women who are pregnant or breastfeeding
- Use of oral contraceptives, patch, ring, intrauterine or implantable hormonal contraception within 4-weeks;
- Medroxyprogesterone acetate use within six months;
- Current use of drugs that interfere with sex steroid metabolism.
Data sourced from ClinicalTrials.gov (NCT01469585). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.